Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGB-Ex01 in Transfusion-dependent β Thalassemia
NCT06041620Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2023
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of VGB-Ex01 in beta thalassemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of adverse events and serious adverse events at 24 months and Number of subjects with neutrophil implantation ≤ 42 days. Started Aug 2023; status: terminated.
02
Drugs
VGB-Ex01
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06041620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041620.